申请人:AnaMar AB
公开号:EP3753924A1
公开(公告)日:2020-12-23
The present invention relates to tricyclic 1-amidino-4-methyl-[2,3-fused]-2-pyrroline derivatives of the general formula I
The invention specifically relates to such derivatives which exhibit antagonizing activity towards serotonin 5-HT2B receptors. The present invention also relates to use of said compounds as a medicament and for the treatment of fibrosis, cardiovascular diseases, pain, IBD, inflammatory diseases, and cancer, as well as pharmaceutical compositions comprising one or more of said compounds and methods of treatment.
本发明涉及通式 I 的三环 1-氨基-4-甲基-[2,3-融合]-2-吡咯啉衍生物
本发明特别涉及对血清素 5-HT2B 受体具有拮抗活性的此类衍生物。本发明还涉及将所述化合物用作药物和用于治疗纤维化、心血管疾病、疼痛、IBD、炎症性疾病和癌症,以及包含一种或多种所述化合物的药物组合物和治疗方法。